altamiratherapeutics.com (CYTO): Stock Quotes

The price characteristics of Altamira Therapeutics (CYTO) on the GURU.Markets platform, with a value of 0.30, support the business of Altamira Therapeutics, which is building a foundation for the medicine of the future by implementing the SemaPoly system in the treatment of inflammation and cancer. The company relies on OligoPhore patents to secure contracts with global industry leaders. Current R&D expenses are covered through the issuance of new shares and the divestment of legacy assets.

altamiratherapeutics.com - CYTO Price (period 07/04/2022 - 01/04/2025)

Auris Medical - analytical breakdowns and key metrics (CYTO)

- stock quotes and analyst forecast:

Stock Price Altamira Therapeutics|CYTO - Consensus Target

- stock exchange capitalization data:

Market Valuation Altamira Therapeutics Ltd|CYTO - Total Enterprise Value

- issuer book value statistics:

Accounting Value per Share Altamira Therapeutics|CYTO - Total Net Assets|Market Value to Book Value Ratio altamiratherapeutics.com|CYTO - Company Assets

- debt level and financial liquidity data:

- financial results and valuation multiples details:

CYTO - Net Income|Projected Future Earnings Altamira Therapeutics|CYTO - P/E Multiple|Projected Price to Earnings Altamira Therapeutics|CYTO - Growth-Adjusted Payback Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Altamira Therapeutics Ltd|CYTO - Profit before interest, taxes and amortization|Net earnings per share for the last 12 months Altamira Therapeutics|CYTO - Earnings per share for the last four quarters|Quarterly EPS earnings growth altamiratherapeutics.com|CYTO - Earnings per share increase in current year|Earnings growth forecast for next year Altamira Therapeutics

Fundamental valuation:Altamira Therapeutics Ltd.

The price captures the current market consensus between buyers and sellers, reflecting a real-time valuation of all fundamental investor expectations for the asset. By analyzing the price chart of Altamira Therapeutics (CYTO), one can track how the market re-evaluates the potential of the OligoPhore platform for targeted RNA delivery to tumors, thereby determining the investment resilience of the biotech business.

Analysis of competing companies